石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

交易中 11-05 10:18:49

2.685

+0.065

+2.48%

最高2.710	最低2.645	成交量232.20万
今开2.660	昨收2.620	日振幅2.48%
总市值77.46亿	流通市值77.46亿	总股本28.85亿
成交额624.44万	换手率0.08%	流通股本28.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.685,"timestamp":1793845081637,"preClose":2.62,"halted":0,"volume":2322000,"delay":0,"changeRate":0.02480916030534349,"floatShares":2885000000,"shares":2885000000,"eps":0.1605,"marketStatus":"交易中","change":0.065,"latestTime":"11-05 10:18:49","open":2.66,"high":2.71,"low":2.645,"amount":6244410,"amplitude":0.024809,"askPrice":2.69,"askSize":56000,"bidPrice":2.68,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":0.174609,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1793851200000},"marketStatusCode":2,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.62,"dividendRate":0.03162,"openAndCloseTimeList":[[1793842200000,1793851200000],[1793854800000,1793865600000]],"volumeRatio":2.995319,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2680746319","title":"石四药集团：阿奇霉素分散片（0.25g）获一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2680746319","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680746319?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:41","pubTimestamp":1793695260,"startTime":"0","endTime":"0","summary":"11月3日，石四药集团（02005）发布公告，本集团的阿奇霉素分散片（0.25g）已取得中国国家药品监督管理局批准通过仿制药质量和疗效一致性评价。阿奇霉素是一种大环内酯类抗菌药物，主要用于治疗由指定微生物敏感菌株引起的轻度至中度感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920296077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920296077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145202276","title":"石四药集团(02005)阿奇霉素分散片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=1145202276","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145202276?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:38","pubTimestamp":1793695118,"startTime":"0","endTime":"0","summary":"石四药集团有限公司(02005)11月3日公告称，集团生产的阿奇霉素分散片(0.25g)已获中国国家药品监督管理局批准，通过仿制药质量和疗效一致性评价。阿奇霉素属于大环内酯类抗菌药物，适用于治疗由指定微生物敏感菌株引起的轻度至中度感染。该公告为自愿发布，旨在向股东及潜在投资者披露最新业务进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680745850","title":"石四药集团(02005.HK)：阿奇霉素分散片(0.25g)通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2680745850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680745850?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:32","pubTimestamp":1793694759,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195300940","title":"石四药集团更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1195300940","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195300940?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:46","pubTimestamp":1793609204,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年11月2日披露截至2026年10月31日的股份变动月报表。公告显示，公司本月注册股本维持在10,000,000,000股，面值每股0.02港元，总额为200,000,000港元，与上月底保持一致。与此同时，公司于2023年1月13日通过的购股权计划在本月未有行使或授出变动，目前仍对应可行使的潜在发行股份数为297,268,338股。该公告由执行董事兼公司秘书周兴扬签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181846309","title":"石四药集团(02005)苹果酸奈诺沙星原料药获国家药监局批准登记","url":"https://stock-news.laohu8.com/highlight/detail?id=1181846309","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181846309?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:36","pubTimestamp":1793262989,"startTime":"0","endTime":"0","summary":"石四药集团有限公司(02005)10月29日公告称，其苹果酸奈诺沙星已获中国国家药品监督管理局批准登记，成为在上市制剂中使用的原料药。苹果酸奈诺沙星为抗感染药物，适用于治疗对奈诺沙星敏感的肺炎链球菌、金黄色葡萄球菌、流感嗜血杆菌、副流感嗜血杆菌、卡他莫拉菌、肺炎克雷伯菌、铜绿假单胞菌以及肺炎支原体、肺炎衣原体和嗜肺军团菌引起的成人社区获得性肺炎。此次公告为公司自愿披露，用以向股东及潜在投资者通报最新业务进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103980493","title":"石四药集团(02005)限制性股份奖励计划再购40万股 涉资约104.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103980493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103980493?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:36","pubTimestamp":1793176572,"startTime":"0","endTime":"0","summary":"石四药集团有限公司10月28日发布自愿公告称，其于2018年12月27日采纳的限制性股份奖励计划下，受托人已于2026年10月28日在公开市场合共购入40万股公司股份，所涉股份将以信托方式持有并用于未来授予获选参与者。董事会表示，将不时检讨并全权酌情决定向获选参与者授予的股份数量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678459723","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459723","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459723?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:33","pubTimestamp":1793176394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年10月28日，由本公司内部资源拨付，计划受托人根据限制性股份奖励计划的条款及条件在公开市场上购买合共40万股本公司股份，并以信托方式为获选参与者持有该等股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165781527","title":"石四药集团（02005）披露2026财年前三季度未经审计业绩：营收35.20亿港元，同比增长13.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165781527","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165781527?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:36","pubTimestamp":1793003812,"startTime":"0","endTime":"0","summary":"石四药集团10月26日自愿公告，截至2026年9月30日止九个月，公司未经审计的合并营收约为35.20亿港元，较2025年同期的31.02亿港元增长13.5%。同期，集团实现未经审计毛利约14.42亿港元，较上年同期的12.94亿港元增加11.4%；毛利率为41.0%，同比下降0.7个百分点。归属于股东的未经审计利润约4.60亿港元，较上年同期的3.99亿港元增长15.5%。石四药集团指出，本次业绩数据来源于未经审计的管理账目，仅供参考，最终经审计结果或有差异。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168718","title":"石四药集团(02005)前三季度股东应占溢利约4.60亿港元 同比增加15.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168718","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678168718?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:33","pubTimestamp":1793003597,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团截至2026年9月30日止九个月之未经审核营业额约35.20亿港元(2025年同期：约31.02亿港元)，同比增加13.5%，主要由于本集团静脉输液及原料药业务恢复增长。本集团截至2026年9月30日止九个月之未经审核毛利约14.42亿港元(2025年同期：约12.94亿港元)，同比增加11.4%，其未经审核毛利率约为41.0%，同比减少0.7百分点。截至2026年9月30日止九个月，本集团之未经审核本公司股东应占溢利约 4.60亿港元，同比增加15.5%(2025年同期：约3.99亿港元)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677980236","title":"石四药集团(02005)：盐酸拉贝洛尔已获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2677980236","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677980236?lang=zh_cn&edition=full","pubTime":"2026-10-22 12:10","pubTimestamp":1792642253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的盐酸拉贝洛尔已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸拉贝洛尔主要用于治疗高血压。此产品的制剂为妊娠期高血压一线急救用药。集团已持有盐酸拉贝洛尔注射液制剂批件。本次原料药获批是集团原料药制剂一体化战略的重要实践。目前，集团高血压管线已构建覆盖常规慢病口服单药、固定复方制剂、高血压急症及产科静脉用药的完整产品梯队。依托多类核心降压品种的原料药与制剂双向布局，集团持续一体化产业链建设，全面覆盖高血压慢病与急救的刚性临床需求，夯实心血管领域产品竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171019729","title":"石四药集团（02005.HK）盐酸拉贝洛尔原料药获国家药监局注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1171019729","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171019729?lang=zh_cn&edition=full","pubTime":"2026-10-22 12:06","pubTimestamp":1792641976,"startTime":"0","endTime":"0","summary":"石四药集团有限公司10月22日发布自愿公告称，集团旗下盐酸拉贝洛尔原料药已获中国国家药品监督管理局批准登记成为在上市制剂中使用的原料药。该产品主要适用于治疗高血压，其注射液制剂已被定位为妊娠期高血压的一线急救用药，而集团此前已持有该注射液的制剂批准文号。公告指出，原料药获批是集团“原料药—制剂一体化”战略的重要实践。公司表示，此次公告为自愿披露，旨在让股东及潜在投资者了解集团最新业务进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149056313","title":"石四药集团(02005)获批化学药品3类色甘酸钠单剂量滴眼液","url":"https://stock-news.laohu8.com/highlight/detail?id=1149056313","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149056313?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:36","pubTimestamp":1792053363,"startTime":"0","endTime":"0","summary":"2026年10月15日，石四药集团有限公司发布自愿公告称，公司已获得中国国家药品监督管理局对色甘酸钠滴眼液2%的药品生产注册批件，产品归属化学药品第3类，视同通过一致性评价。公告称，石四药集团是国内首家以化学药品新3类形式获批色甘酸钠单剂量制剂的企业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675302564","title":"石四药集团(02005.HK)取得国家药监局有关色甘酸钠滴眼液2%(0.3ml:6mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2675302564","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675302564?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:33","pubTimestamp":1792053227,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128071781","title":"石四药集团（02005.HK）获批尼莫地平口服溶液生产注册　完善心脑血管及神经重症产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1128071781","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128071781?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:42","pubTimestamp":1791448922,"startTime":"0","endTime":"0","summary":"石四药集团有限公司10月8日发布自愿公告称，公司已取得中国国家药品监督管理局核发的“尼莫地平口服溶液”药品生产注册批件。公告显示，尼莫地平口服溶液主要用于治疗因颅内囊性动脉瘤破裂导致蛛网膜下腔出血的成人患者，可通过降低缺血性神经损伤的发生率和严重程度来改善神经系统预后。石四药集团此前于2025年3月19日公告，其尼莫地平原料药已获国家药监局批准登记为上市制剂所用原料药。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123694506","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123694506","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123694506?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:42","pubTimestamp":1790934174,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年10月2日以每股均价2.7696港元场外买入石四药集团（02005）50.00万股，涉资约138.48万港元。该笔为场外交易（自愿披露），未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.25亿股，占比31.33%；增持后持股量为9.25亿股，好仓比例升至31.35%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180478572","title":"石四药集团公布9月股份变动月报表，回购655万股转为库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1180478572","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180478572?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:41","pubTimestamp":1790934108,"startTime":"0","endTime":"0","summary":"石四药集团于2026年10月2日发布2026年9月股份变动月报表。该报告期为截至2026年9月30日，反映了公司在9月份的股本结构和股份变动情况。9月内，公司回购6,550,000股并将其全数转为库存。截至9月底，已发行股份数量变更为2,884,893,385股，库存股份增至66,220,000股，总股本仍维持在2,951,113,385股。自本次回购后，截至2026年9月30日，石四药集团的股本总数仍保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108543116","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108543116","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108543116?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:50","pubTimestamp":1790675432,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月29日以每股均价2.7812港元场外买入石四药集团（02005）股份150.00万股，涉资约417.18万港元。该笔交易为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.23亿股，占比31.28%；增持后持股量为9.25亿股，好仓比例升至31.33%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154407258","title":"石四药集团(02005)公布董事会及三大委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1154407258","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154407258?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:22","pubTimestamp":1790594528,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月28日发布公告，披露公司董事会及其下属三大委员会最新成员组成情况。公告显示，董事会由执行董事、非执行董事及独立非执行董事共九名成员组成。执行董事兼主席兼行政总裁为曲继广；其他执行董事为孟国、周兴扬、曲婉蓉和吴恒耀。独立非执行董事包括王亦兵、周国伟及姜广策。公告称，上述安排自公布之日起生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123940789","title":"石四药集团任命吴恒耀为执行董事 苏学军同日辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1123940789","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123940789?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:16","pubTimestamp":1790594189,"startTime":"0","endTime":"0","summary":"石四药集团有限公司9月28日发布董事局公告称，自2026年9月28日起：吴恒耀先生获委任为执行董事；苏学军先生因专注其他工作安排辞任执行董事。吴恒耀，57岁，现任公司全资附属公司新东投资医药控股（香港）有限公司及石家庄四药有限公司董事，并担任石家庄四药总裁。截至公告日期，董事局成员包括执行董事曲继广、孟国、周兴扬、曲婉蓉及吴恒耀；非执行董事刘文军；独立非执行董事王亦兵、周国伟及姜广策。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670231616","title":"石四药集团(02005)：吴恒耀获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2670231616","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670231616?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:14","pubTimestamp":1790594092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，自2026年9月28日起：1.吴恒耀先生获委任为执行董事;及2.苏学军先生因有意专注彼的其他工作安排而辞任执行董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.1308},{"period":"6month","weight":0.1288},{"period":"1year","weight":-0.1175},{"period":"ytd","weight":-0.0427}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.005},{"period":"3month","weight":-0.0631},{"period":"6month","weight":-0.0937},{"period":"1year","weight":-0.0783},{"period":"ytd","weight":-0.0668}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008129},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020564},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079144},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030994},{"month":5,"riseRate":0.47619,"avgChangeRate":0.01054},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060529},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.020932},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.010111},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.041628},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.005997},{"month":11,"riseRate":0.666667,"avgChangeRate":0.083019},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009036}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}